Infinity Pharmaceuticals (INFI) has been under a strong bear grip, hence the stock is down -7.44% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.56% in the past 1 week. The stock has risen by 2.1% in the past week indicating that the buyers are active at lower levels, but the stock is down -9.32% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 5.44% and the 50-Day Moving Average is 6.12%.The 200 Day SMA reached 68.48% Infinity Pharmaceuticals, Inc. has dropped 3.95% during the last 3-month period . Year-to-Date the stock performance stands at -81.4%.
Infinity Pharmaceuticals (INFI) : The highest short term price target forecast on Infinity Pharmaceuticals (INFI) is $2 and the lowest target price is $1. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $1.6 with a standard deviation of $0.55.
Company shares have received an average consensus rating of Hold for the current week Infinity Pharmaceuticals (NASDAQ:INFI): The stock opened at $1.4 and touched an intraday high of $1.48 on Friday. During the day, the stock corrected to an intraday low of $1.39, however, the bulls stepped in and pushed the price higher to close in the green at $1.46 with a gain of 4.29% for the day. The total traded volume for the day was 993,706. The stock had closed at $1.46 in the previous trading session.
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.